ATE201772T1 - Verfahren und zusammensetzungen zur behandlung von mit bcr-abl assoziierter leukämie und anderen zellproliferativen störungen - Google Patents

Verfahren und zusammensetzungen zur behandlung von mit bcr-abl assoziierter leukämie und anderen zellproliferativen störungen

Info

Publication number
ATE201772T1
ATE201772T1 AT94929384T AT94929384T ATE201772T1 AT E201772 T1 ATE201772 T1 AT E201772T1 AT 94929384 T AT94929384 T AT 94929384T AT 94929384 T AT94929384 T AT 94929384T AT E201772 T1 ATE201772 T1 AT E201772T1
Authority
AT
Austria
Prior art keywords
abl
compositions
methods
cell proliferative
proliferative disorders
Prior art date
Application number
AT94929384T
Other languages
English (en)
Inventor
Joseph Schlessinger
Mikhail L Gishizky
Ann M Pendergast
Harald App
Original Assignee
Univ New York Medical Ct
Sugen Inc
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York Medical Ct, Sugen Inc, Univ Duke filed Critical Univ New York Medical Ct
Application granted granted Critical
Publication of ATE201772T1 publication Critical patent/ATE201772T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT94929384T 1993-09-28 1994-09-28 Verfahren und zusammensetzungen zur behandlung von mit bcr-abl assoziierter leukämie und anderen zellproliferativen störungen ATE201772T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12792293A 1993-09-28 1993-09-28
US08/246,441 US6066463A (en) 1993-09-28 1994-05-20 Method and compositions for treatment of BCR-ABL associated leukemias and other cell proliferative disorders
PCT/US1994/011067 WO1995009365A1 (en) 1993-09-28 1994-09-28 Methods and compositions for treatment of bcr-abl associated leukemias and other cell proliferative disorders

Publications (1)

Publication Number Publication Date
ATE201772T1 true ATE201772T1 (de) 2001-06-15

Family

ID=26826088

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94929384T ATE201772T1 (de) 1993-09-28 1994-09-28 Verfahren und zusammensetzungen zur behandlung von mit bcr-abl assoziierter leukämie und anderen zellproliferativen störungen

Country Status (10)

Country Link
US (3) US6066463A (de)
EP (1) EP0721586B1 (de)
JP (1) JP3606579B2 (de)
CN (1) CN1132011C (de)
AT (1) ATE201772T1 (de)
AU (1) AU693808B2 (de)
CA (1) CA2172961A1 (de)
DE (1) DE69427364T2 (de)
DK (1) DK0721586T3 (de)
WO (1) WO1995009365A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107457A (en) * 1995-02-16 2000-08-22 Board Of Regents, The University Of Texas System Bcr-Abl directed compositions and uses for inhibiting Philadelphia chromosome stimulated cell growth
US5969101A (en) * 1995-10-27 1999-10-19 Duke University ABL-interactor protein
CA2274145A1 (en) * 1996-12-03 1998-06-11 Sugen, Inc. Adaptor protein frs2 and related products and methods
WO1998057177A1 (en) * 1997-06-09 1998-12-17 Regeneron Pharmaceuticals, Inc. Assay systems for leptin-enhancing agents
AU8282798A (en) * 1997-07-01 1999-01-25 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
US6768165B1 (en) * 1997-08-01 2004-07-27 Saifun Semiconductors Ltd. Two bit non-volatile electrically erasable and programmable semiconductor memory cell utilizing asymmetrical charge trapping
US6861442B1 (en) * 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
US20030064061A1 (en) * 2001-07-09 2003-04-03 Whitehead Institute For Biomedical Research Bcr-Abl oligomerization domain polypeptides and uses therefor
US20030083304A1 (en) * 2001-10-09 2003-05-01 Smart Robert C. CCAAT/enhancer binding protein-beta (C/EBPbeta) is a molecular target for cancer treatment
JP2011522212A (ja) * 2007-10-19 2011-07-28 セル・シグナリング・テクノロジー・インコーポレイテツド 癌の分類および使用法
WO2011034919A2 (en) * 2009-09-15 2011-03-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Sh2 domain profiling to characterize tyrosine phosphorylation signaling in cancer
EP3307328A1 (de) * 2015-06-10 2018-04-18 Universität des Saarlandes Mittel und verfahren zur behandlung von b-zell-malignomen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007913A1 (en) * 1992-09-25 1994-04-14 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof
AU5548694A (en) * 1992-11-06 1994-06-08 Warner-Lambert Company Peptide inhibitors of tyrosine kinases and therapeutic uses thereof
CA2113494A1 (en) * 1994-01-14 1995-07-15 Lorri Puil Method for assaying for substances which affect bcr-abl mediated transformation

Also Published As

Publication number Publication date
EP0721586A1 (de) 1996-07-17
CN1137826A (zh) 1996-12-11
EP0721586A4 (de) 1996-09-25
WO1995009365A1 (en) 1995-04-06
AU7846494A (en) 1995-04-18
CA2172961A1 (en) 1995-04-06
CN1132011C (zh) 2003-12-24
US6528270B1 (en) 2003-03-04
EP0721586B1 (de) 2001-05-30
DK0721586T3 (da) 2001-07-30
AU693808B2 (en) 1998-07-09
DE69427364D1 (de) 2001-07-05
JP3606579B2 (ja) 2005-01-05
JPH09505730A (ja) 1997-06-10
US6066463A (en) 2000-05-23
US20030092079A1 (en) 2003-05-15
DE69427364T2 (de) 2002-06-20

Similar Documents

Publication Publication Date Title
MX9709442A (es) Metodo y composiciones para la inhibicion de interacciones entre proteina adaptadora y tirosinquinasa.
DE69427364D1 (de) Verfahren und zusammensetzungen zur behandlung von mit bcr-abl assoziierter leukämie und anderen zellproliferativen störungen
TR199902194T2 (xx) +p38 protein kinaz inhibit�rleri olarak ikameli azot ihtiva eden heterosikler.
DE69914726D1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
DE60027551D1 (de) Zusammensetzungen und verfahren zur regulierung des serumcholesterins
ATE230757T1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
BG104356A (en) Compounds based on azabenzimidazole for the modulation of serin/treonin protein kinase function
DE69634912D1 (de) Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren
TR199900049T2 (xx) Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler.
ATE333888T1 (de) Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
ATE547101T1 (de) Verfahren zur verwendung von diketopiperazinen und zusammensetzungen, die diese enthalten
ATE231970T1 (de) Verfahren zur messung chemischer und physikalischer parameter zur charakterisierung und klassifizierung von wässrigen suspensionen
DE60107252D1 (de) Antimikrobielle zusammensetzung zur behandlung von rindermastitis
ATE313802T1 (de) Bestimmung von adrenomedullin-bindenden proteinen
ATE181235T1 (de) Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen
BG100930A (bg) Фармацевтични състави и лекарствени средства за профилактика и лечение на ендотелиални нарушения
NO913684D0 (no) Fremgangsmaate for fremstilling av kalsiumopptaksinhibitorer.
DE69535131D1 (de) Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
NO20010389L (no) Modulering av multippel linje kinase proteiner
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
DE60024997D1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE60140074D1 (de) Non-apoptotische formen des zelltods und verfahren zur modulation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties